Joseph Chen

2.0k total citations · 1 hit paper
27 papers, 801 citations indexed

About

Joseph Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Joseph Chen has authored 27 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Joseph Chen's work include Lung Cancer Treatments and Mutations (10 papers), Cancer therapeutics and mechanisms (9 papers) and Lung Cancer Research Studies (5 papers). Joseph Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer therapeutics and mechanisms (9 papers) and Lung Cancer Research Studies (5 papers). Joseph Chen collaborates with scholars based in United States, Australia and Spain. Joseph Chen's co-authors include Leonard P. James, Jean‐François Martini, Jill S. Clancy, Enriqueta Felip, Alice T. Shaw, Benjamin Solomon, Melissa L. Johnson, Todd M. Bauer, Antonello Abbattista and Jörg Dietrich and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Joseph Chen

27 papers receiving 787 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

2017 487 citations Alice T. Shaw, Enriqueta Felip et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph Chen United States	13	527	452	240	110	53	27	801
Paolo De Giuli Italy	15	384 0.7×	454 1.0×	331 1.4×	137 1.2×	88 1.7×	19	1.2k
Davide Lombardi Italy	17	308 0.6×	609 1.3×	210 0.9×	211 1.9×	61 1.2×	57	1.0k
Raffaele Costanzo Italy	16	368 0.7×	563 1.2×	277 1.2×	147 1.3×	54 1.0×	53	899
Sasja F. Mulder Netherlands	12	340 0.6×	253 0.6×	265 1.1×	130 1.2×	34 0.6×	38	669
Nicoletta Cordani Italy	14	282 0.5×	223 0.5×	311 1.3×	105 1.0×	43 0.8×	29	739
Damiano Italy	6	446 0.8×	634 1.4×	346 1.4×	72 0.7×	47 0.9×	11	885
Axel R. Hanauske Germany	11	490 0.9×	425 0.9×	426 1.8×	132 1.2×	88 1.7×	19	1.0k
Peter F. Lenehan United States	14	417 0.8×	466 1.0×	270 1.1×	127 1.2×	78 1.5×	18	831
Toshio Fujino Japan	16	563 1.1×	420 0.9×	402 1.7×	142 1.3×	105 2.0×	54	975
A. Craig Lockhart United States	17	261 0.5×	477 1.1×	522 2.2×	234 2.1×	87 1.6×	49	1.0k

Countries citing papers authored by Joseph Chen

Since Specialization

Citations

This map shows the geographic impact of Joseph Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Chen more than expected).

Fields of papers citing papers by Joseph Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Chen. The network helps show where Joseph Chen may publish in the future.

Co-authorship network of co-authors of Joseph Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Chen. A scholar is included among the top collaborators of Joseph Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Chen. Joseph Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elmeliegy, Mohamed, et al.. (2024). Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology. Clinical Pharmacology & Therapeutics. 116(3). 637–646. 9 indexed citations

Qin, Songbing, Wei Tian, Mingqiang Li, et al.. (2023). 1054P A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors. Annals of Oncology. 34. S638–S638. 5 indexed citations

Chen, Joseph, Alessandra Bearz, Dong‐Wan Kim, et al.. (2023). Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Pharmacokinetics. 63(2). 171–182. 3 indexed citations

Piscitelli, Joseph, et al.. (2022). The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. Clinical Drug Investigation. 42(3). 221–235. 4 indexed citations

Li, Jerry, Yazdi K. Pithavala, Jason Gong, et al.. (2021). The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants. Clinical Pharmacokinetics. 60(10). 1303–1312. 7 indexed citations

Chen, Joseph, et al.. (2021). Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study. Clinical Pharmacokinetics. 60(10). 1313–1324. 21 indexed citations

Hu, Wenyue, Daniel J. Lettiere, Susanna Tse, et al.. (2021). Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity. Toxicological Sciences. 182(2). 183–194. 5 indexed citations

Chen, Joseph, Ana Ruiz-Garcı́a, Leonard P. James, et al.. (2021). Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 110(5). 1273–1281. 16 indexed citations

Chen, Joseph, Brett E. Houk, Yazdi K. Pithavala, & Ana Ruiz-Garcı́a. (2021). Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants. CPT Pharmacometrics & Systems Pharmacology. 10(2). 148–160. 16 indexed citations

10.

Chen, Joseph, et al.. (2020). Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical and Translational Science. 14(1). 184–193. 3 indexed citations

11.

Taslimi, Shervin, Jeffrey Zuccato, Alireza Mansouri, et al.. (2019). Novel Statistical Analyses to Assess Hearing Outcomes After ABI Implantation in NF2 Patients: Systematic Review and Individualized Patient Data Analysis. World Neurosurgery. 128. e669–e682. 3 indexed citations

12.

Chen, Joseph, Alessandra Bearz, D. Kim, et al.. (2019). P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S392–S393. 2 indexed citations

13.

Chen, Joseph, Huiping Xu, Sylvester Pawlak, et al.. (2019). The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. Advances in Therapy. 37(2). 745–758. 24 indexed citations

14.

Patel, Maulik, et al.. (2019). The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. Investigational New Drugs. 38(1). 131–139. 17 indexed citations

15.

Shaw, Alice T., Enriqueta Felip, Todd M. Bauer, et al.. (2017). Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. The Lancet Oncology. 18(12). 1590–1599. 487 indexed citations breakdown →

16.

Shet, Narendra, Joseph Chen, & Eliot L. Siegel. (2011). Continuing challenges in defining image quality. Pediatric Radiology. 41(5). 582–587. 24 indexed citations

17.

Malinoski, Darren, Madhukar S. Patel, Joseph Chen, et al.. (2010). Inhibition of Intraluminal Pancreatic Enzymes With Nafamostat Mesilate Improves Clinical Outcomes After Hemorrhagic Shock in Swine. The Journal of Trauma: Injury, Infection, and Critical Care. 68(5). 1078–1083. 7 indexed citations

18.

Chen, Joseph, et al.. (2007). ESTROGEN EXPOSURE FROM BIRTH AFFECTS UTERINE GENE EXPRESSION IN NEONATAL GILTS THAT PERSISTS IN PREGNANT ADULTS. Biology of Reproduction. 77(Suppl_1). 152–152. 1 indexed citations

19.

Gibson, G. R., et al.. (2004). Characterization of a tissue factor/factor VIIa‐dependent model of thrombosis in hypercholesterolemic rabbits. Journal of Thrombosis and Haemostasis. 2(1). 85–92. 18 indexed citations

20.

Tarnawski, Andrzej S., et al.. (2002). Low dose ethanol potentiates indomethacin induced inhibition of wound re-epithelialization in duodenal monolayers. Life Sciences. 70(26). 3143–3153. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact